Cerus Corp (CERS) — 分析摘要
Cerus Corp（CERS）的市值为433.28百万美元，最近一年的营收同比增长了+16.1%。净利润率为-6.7%。当前市盈率为-63.9倍。
核心要点
- 营收同比变化+16.1%
- 净利润率-6.7%
- 市盈率-63.9倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，CERS的营收增长为+16.1%，市盈率为-63.9倍。
Cerus Corp (CERS)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
Debt/EBITDA 为 986.2x — 高杠杆，存在再融资风险
利息保障倍数为 -0.2x — 盈利不足以覆盖利息支出
营收较上一期下降 100.0%。
自由现金流由上一期为正转为负。
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
345
总部
CONCORD, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。